JPWO2021061853A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021061853A5 JPWO2021061853A5 JP2022518768A JP2022518768A JPWO2021061853A5 JP WO2021061853 A5 JPWO2021061853 A5 JP WO2021061853A5 JP 2022518768 A JP2022518768 A JP 2022518768A JP 2022518768 A JP2022518768 A JP 2022518768A JP WO2021061853 A5 JPWO2021061853 A5 JP WO2021061853A5
- Authority
- JP
- Japan
- Prior art keywords
- days
- immune cells
- expanded
- cbl
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962905124P | 2019-09-24 | 2019-09-24 | |
| US62/905,124 | 2019-09-24 | ||
| US201962954323P | 2019-12-27 | 2019-12-27 | |
| US62/954,323 | 2019-12-27 | ||
| US202062961596P | 2020-01-15 | 2020-01-15 | |
| US62/961,596 | 2020-01-15 | ||
| US202062978254P | 2020-02-18 | 2020-02-18 | |
| US62/978,254 | 2020-02-18 | ||
| US202063032462P | 2020-05-29 | 2020-05-29 | |
| US63/032,462 | 2020-05-29 | ||
| PCT/US2020/052317 WO2021061853A1 (en) | 2019-09-24 | 2020-09-23 | Cbl inhibitors and compositions for use in adoptive cell therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022549007A JP2022549007A (ja) | 2022-11-22 |
| JPWO2021061853A5 true JPWO2021061853A5 (https=) | 2023-10-03 |
| JP2022549007A5 JP2022549007A5 (https=) | 2023-10-03 |
Family
ID=72811970
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022518710A Pending JP2022549303A (ja) | 2019-09-24 | 2020-09-23 | 免疫細胞を拡大増殖するためのｃｂｌ阻害剤および組成物 |
| JP2022518768A Pending JP2022549007A (ja) | 2019-09-24 | 2020-09-23 | 養子細胞療法に使用するためのｃｂｌ阻害剤および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022518710A Pending JP2022549303A (ja) | 2019-09-24 | 2020-09-23 | 免疫細胞を拡大増殖するためのｃｂｌ阻害剤および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12121540B2 (https=) |
| EP (2) | EP4034141A1 (https=) |
| JP (2) | JP2022549303A (https=) |
| KR (2) | KR20220068227A (https=) |
| CN (2) | CN114786687A (https=) |
| AU (2) | AU2020352609A1 (https=) |
| CA (2) | CA3152281A1 (https=) |
| IL (2) | IL291579A (https=) |
| WO (2) | WO2021061870A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019148005A1 (en) * | 2018-01-26 | 2019-08-01 | Nurix Therapeutics, Inc. | Inhibitors of cbl-b and methods of use thereof |
| JP7600123B2 (ja) | 2018-10-15 | 2024-12-16 | ニューリックス セラピューティクス，インコーポレイテッド | ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物 |
| WO2020167518A1 (en) | 2019-02-13 | 2020-08-20 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| EP3953346A1 (en) | 2019-04-09 | 2022-02-16 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| EP3969447A1 (en) | 2019-05-17 | 2022-03-23 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof |
| MX2021015675A (es) | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| EP4034141A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for expansion of immune cells |
| US11820781B2 (en) | 2019-12-04 | 2023-11-21 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| US12365871B2 (en) | 2020-04-28 | 2025-07-22 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| US12016860B2 (en) | 2021-04-08 | 2024-06-25 | Nurix Therapeutics, Inc. | Combination therapies with Cbl-b inhibitor compounds |
| AU2022379494A1 (en) | 2021-10-26 | 2024-05-30 | Nurix Therapeutics, Inc. | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
| JP2024542117A (ja) * | 2021-11-05 | 2024-11-13 | ジェネンテック， インコーポレイテッド | Ｃ－ｃｂｌに対して選択的なｃｂｌ－ｂ阻害剤としてのラクタム |
| TW202342013A (zh) * | 2022-02-10 | 2023-11-01 | 英屬開曼群島商百濟神州有限公司 | 雜環化合物、其組成物及用其進行治療之方法 |
| CN119212724A (zh) * | 2022-05-09 | 2024-12-27 | 上海先博生物科技有限公司 | 工程化免疫效应细胞及其与CBL-b抑制剂联用的应用 |
| WO2023250097A1 (en) * | 2022-06-22 | 2023-12-28 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds and antiemetic agents |
| JP2025525947A (ja) | 2022-08-16 | 2025-08-07 | グレンマーク ファーマシューティカルズ エルティーディー | Ｃｂｌ－ｂ阻害剤としての置換ピリジノン化合物 |
| WO2024062363A1 (en) * | 2022-09-21 | 2024-03-28 | Glenmark Pharmaceuticals Ltd | Bicyclic heterocyclic compounds as cbl-b inhibitors |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5273986A (en) | 1992-07-02 | 1993-12-28 | Hoffmann-La Roche Inc. | Cycloalkylthiazoles |
| CA2437248A1 (en) | 2001-02-02 | 2002-08-15 | Takeda Chemical Industries, Ltd. | Jnk inhibitor |
| WO2004099388A2 (en) | 2003-03-05 | 2004-11-18 | Proteologics, Inc. | Cbl-b polypeptides, complexes and related methods |
| US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| CN101365806B (zh) | 2005-12-01 | 2016-11-16 | 医学预后研究所 | 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途 |
| ES2566502T3 (es) * | 2006-09-13 | 2016-04-13 | The Trustees Of Columbia University In The City Of New York | Agentes y métodos para provocar una respuesta inmune antitumoral |
| AT506041A1 (de) * | 2007-12-10 | 2009-05-15 | Univ Innsbruck | Verfahren zur erhöhung der immunreaktivität |
| CA2710462C (en) | 2008-02-05 | 2015-11-24 | F. Hoffmann-La Roche Ag | Pyridinones and pyridazinones |
| AR079545A1 (es) | 2009-12-21 | 2012-02-01 | Bayer Cropscience Ag | Tienilpiri(mi)dinilazol |
| KR101862327B1 (ko) | 2010-05-07 | 2018-05-29 | 질레드 코네티컷 인코포레이티드 | 피리돈 및 아자-피리돈 화합물 및 사용 방법 |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| EP2471548A1 (de) * | 2010-12-28 | 2012-07-04 | Apeiron Biologics AG | siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs |
| WO2012175513A1 (en) | 2011-06-20 | 2012-12-27 | Bayer Intellectual Property Gmbh | Thienylpyri(mi)dinylpyrazole |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| WO2013067264A1 (en) | 2011-11-03 | 2013-05-10 | Genentech, Inc. | 8-fluorophthalazin-1 (2h) - one compounds as inhibitors of btk activity |
| KR20150054994A (ko) | 2012-09-13 | 2015-05-20 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나아제의 억제제 |
| US10308707B2 (en) | 2013-12-02 | 2019-06-04 | Aaron Diamond Aids Research Center | Bispecific HIV-1-neutralizing antibodies |
| AU2014360446A1 (en) | 2013-12-05 | 2016-06-09 | Pharmacyclics, Llc | Inhibitors of Bruton's tyrosine kinase |
| BR112017025986A2 (pt) | 2015-06-02 | 2018-08-14 | Pharmacyclics Llc | inibidores de tirosina quinase de bruton. |
| EP3325475B1 (en) | 2015-07-17 | 2020-03-18 | Takeda Pharmaceutical Company Limited | Oxadiazole derivatives useful as hdac inhibitors |
| EP3254701A1 (en) | 2016-06-09 | 2017-12-13 | IMBA-Institut für Molekulare Biotechnologie GmbH | Cbl-b inhibitor comprising a cbl-b binding peptide for the prevention or treatment of fungal infections |
| US10842878B2 (en) | 2016-11-22 | 2020-11-24 | Dana-Farber Cancer Institute, Inc. | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| WO2019148005A1 (en) * | 2018-01-26 | 2019-08-01 | Nurix Therapeutics, Inc. | Inhibitors of cbl-b and methods of use thereof |
| JP7600123B2 (ja) | 2018-10-15 | 2024-12-16 | ニューリックス セラピューティクス，インコーポレイテッド | ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物 |
| WO2020167518A1 (en) | 2019-02-13 | 2020-08-20 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| EP3953346A1 (en) | 2019-04-09 | 2022-02-16 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| EP3969447A1 (en) * | 2019-05-17 | 2022-03-23 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof |
| MX2021015675A (es) | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| WO2021021761A1 (en) | 2019-07-30 | 2021-02-04 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition |
| EP4034141A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for expansion of immune cells |
| US20230024442A1 (en) | 2019-11-08 | 2023-01-26 | Nurix Therapeutics, Inc. | Bifunctional compounds for grading btk via ubiquitin proteosome pathway |
| US11820781B2 (en) | 2019-12-04 | 2023-11-21 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
-
2020
- 2020-09-23 EP EP20803324.1A patent/EP4034141A1/en active Pending
- 2020-09-23 WO PCT/US2020/052335 patent/WO2021061870A1/en not_active Ceased
- 2020-09-23 US US17/030,335 patent/US12121540B2/en active Active
- 2020-09-23 KR KR1020227011154A patent/KR20220068227A/ko not_active Ceased
- 2020-09-23 WO PCT/US2020/052317 patent/WO2021061853A1/en not_active Ceased
- 2020-09-23 AU AU2020352609A patent/AU2020352609A1/en not_active Abandoned
- 2020-09-23 CA CA3152281A patent/CA3152281A1/en active Pending
- 2020-09-23 CN CN202080081550.4A patent/CN114786687A/zh active Pending
- 2020-09-23 CA CA3152293A patent/CA3152293A1/en active Pending
- 2020-09-23 AU AU2020353015A patent/AU2020353015A1/en not_active Abandoned
- 2020-09-23 JP JP2022518710A patent/JP2022549303A/ja active Pending
- 2020-09-23 US US17/030,258 patent/US12594263B2/en active Active
- 2020-09-23 JP JP2022518768A patent/JP2022549007A/ja active Pending
- 2020-09-23 KR KR1020227011316A patent/KR20220068228A/ko not_active Ceased
- 2020-09-23 EP EP20789344.7A patent/EP4034140A1/en active Pending
- 2020-09-23 CN CN202080081556.1A patent/CN114761027A/zh active Pending
-
2022
- 2022-03-21 IL IL291579A patent/IL291579A/en unknown
- 2022-03-21 IL IL291577A patent/IL291577A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12419870B2 (en) | Compositions and methods for immune cell modulation in adoptive immunotherapies | |
| JPWO2021061853A5 (https=) | ||
| AU2020204267B2 (en) | Compositions and methods for immune cell modulation in adoptive immunotherapies | |
| JP7098615B2 (ja) | 養子免疫療法における免疫細胞調節のための組成物および方法 | |
| Riggan et al. | Arrested development: suppression of NK cell function in the tumor microenvironment | |
| Vuckovic et al. | Bone marrow transplantation generates T cell–dependent control of myeloma in mice | |
| Kagamu et al. | Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes | |
| Lewis et al. | A reproducible method for the expansion of mouse CD8+ T lymphocytes | |
| TWI757785B (zh) | 細胞激素誘導記憶型自然殺手細胞及其方法 | |
| CN117295515A (zh) | 用于癌症免疫治疗的嵌合抗原受体修饰的粒细胞-巨噬细胞祖细胞 | |
| US20040258661A1 (en) | Generation of use of tc1 and tc2 cells | |
| CN112074280A (zh) | 前列腺癌特异性骨髓浸润淋巴细胞及其用途 | |
| JPWO2021061870A5 (https=) | ||
| Takatsuki et al. | Analysis of alloreactivity and intragraft cytokine profiles in living donor liver transplant recipients with graft acceptance | |
| Plain et al. | Cytokines affecting CD4+ T regulatory cells in transplant tolerance. Interleukin-4 does not maintain alloantigen specific CD4+ CD25+ Treg | |
| US20040175827A1 (en) | Methods of generating human cd4+ th2 cells and uses thereof | |
| Peng et al. | A cultured malignant B-1 line serves as a model for Richter's syndrome. | |
| EP3440196A1 (en) | Method for preparing lymphocytes capable of infiltrating a solid tumor, lymphocytes obtainable by said method and uses thereof | |
| JP2023521671A (ja) | Ｃｏｖｉｄ－１９感染症に対する幹細胞免疫調節療法 | |
| US20240000843A1 (en) | Compositions and methods for inhibiting or screening for cd8 and methods and assays for detecting cd8 in cells | |
| US12558424B2 (en) | T cells having enhanced anti-tumor activity | |
| US20230127263A1 (en) | Modified t cells and methods of preparing the same | |
| AU2023201552B2 (en) | Compositions and methods for immune cell modulation in adoptive immunotherapies | |
| TWI913728B (zh) | 嵌合抗原受體t細胞療法 | |
| WO2025008798A1 (en) | Compositions and methods for culturing t cells |